Poseida Therapeutics, a Phase 2 biotech developing CAR T cell therapies for multiple myeloma, announced terms for its IPO on Monday.
The San Diego, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoint of the pr
Vasta Platform, a K-12 educational technology provider in Brazil being spun out of Cogna, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The company has developed a "Platform as a Service" with two main modules: its Content & EdTe
Following the long weekend, two Chinese IPOs and a preclinical biotch are currently scheduled to list in the US in the week ahead: China’s largest LGBTQ dating app BlueCity (BLCT), on-demand worker platform Quhuo (QH), and preclinical oncology biotech Nkarta (NKTX)
More dea
Three IPOs raised $2.3 billion this past week, led by Dun & Bradstreet's (DNB) billion-dollar deal. All three IPOs upsized their deals and priced above the range.
Commercial data analytics provider Dun & Bradstreet (DNB) raised $1.7 billion at a $9 billion market cap. Th
East Resources Acquisition, a blank check company formed by Terrence Pegula targeting the North American energy industry, filed on Thursday with the SEC to raise up to $300 million in an initial public offering.
The Boca Raton, FL-based company plans to raise $300 million by offe
PaxMedica, a Phase 2 biotech developing therapies for neurodevelopmental disorders, filed on Thursday with the SEC to raise up to $17 million in an initial public offering.
The company's lead candidate PAX-101, an intravenous formulation of suramin, is currently in a Phase 2B cli
PaxMedica, a Phase 2 biotech developing therapies for neurodevelopmental disorders, filed on Thursday with the SEC to raise up to $17 million in an initial public offering.
The company's lead candidate PAX-101, an intravenous formulation of suramin, is currently in a Phase 2B cli
Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, announced terms for its IPO on Thursday.
The South San Francisco, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the mid
Sun BioPharma, a clinical-stage biotech developing small molecule therapies for pancreatic cancer, filed on Thursday with the SEC to raise up to $12 million in an initial public offering. The company is currently listed on the OTCQB (SNBP) and has a market cap of $42 million.
The
CN Energy, which produces wood-based activated carbon and biomass energy, filed on Thursday with the SEC to raise up to $23 million in an initial public offering.
The Hangzhou, China-based company plans to raise $23 million by offering 5 million shares at a price range of $4 to $
Inozyme Pharma, a preclinical biotech developing therapies for diseases of abnormal mineralization, filed on Thursday with the SEC to raise up to $86 million in an initial public offering.
The company's lead candidate, INZ-701, is a soluble, genetically engineered fusio
Vertex, which provides comprehensive tax software for businesses, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
Vertex delivers comprehensive tax solutions and derives its revenue from software subscriptions and services. It automa
Ascendant Digital Acquisition, a blank check company targeting an interactive digital entertainment business, filed on Thursday with the SEC to raise up to $300 million in an initial public offering.
The New York, NY-based company plans to raise $300 million by offering 30 millio
Property Solutions Acquisition, a blank check company formed by Benchmark Real Estate Group targeting the real estate industry, filed on Thursday with the SEC to raise up to $200 million in an initial public offering.
The New York, NY-based company plans to raise $200 million by
Capstar Special Purpose Acquisition, a blank check company formed by investment firm Capstar Partners, raised $240 million by offering 24 million units at $10. The company offered 4 million more units than anticipated. Each unit consists of one share of common stock and one-half
Accolade, which provides a healthcare benefits management platform for self-insured employers, raised $220 million by offering 10 million shares at $22, above the range of $19 to $21. The company offered 1.3 million more shares than anticipated. At pricing, the company commands a
Lemonade, which provides online self-serve renters and homeowners insurance, raised $319 million by offering 11 million shares at $29, above the upwardly revised range of $26 to $28. The company had originally filed for a price range of $23 to $26. Baillie Gifford, a new investor
BlueCity Holdings, a leading online LGBTQ community and dating platform in China, announced terms for its IPO on Wednesday. In its latest filing, the company also removed CITIC as an underwriter and added Prime Number Capital and R.F. Lafferty & Co.
The Beijing, China-based c